INSM * logo

Insmed IncorporatedBMV:INSM * Stock Report

Market Cap Mex$671.1b
Share Price
Mex$3.76k
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Insmed Incorporated

BMV:INSM * Stock Report

Market Cap: Mex$671.1b

Insmed (INSM *) Stock Overview

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details

INSM * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 38.3% below our estimate of its fair value

Earnings are forecast to grow 60.76% per year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Shareholders have been diluted in the past year


INSM * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Insmed Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Insmed
Historical stock prices
Current Share PriceUS$3,760.00
52 Week HighUS$3,760.00
52 Week LowUS$1,915.00
Beta1.09
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change967.27%
5 Year Changen/a
Change since IPO916.22%

Recent News & Updates

Recent updates

Shareholder Returns

INSM *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how INSM * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how INSM * performed against the MX Market.

Price Volatility

Is INSM *'s price volatile compared to industry and market?
INSM * volatility
INSM * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: INSM *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine INSM *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19881,271Will Lewiswww.insmed.com

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.

Insmed Incorporated Fundamentals Summary

How do Insmed's earnings and revenue compare to its market cap?
INSM * fundamental statistics
Market capMex$671.15b
Earnings (TTM)-Mex$21.26b
Revenue (TTM)Mex$8.03b
83.6x
P/S Ratio
-31.6x
P/E Ratio

Is INSM * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INSM * income statement (TTM)
RevenueUS$447.02m
Cost of RevenueUS$104.87m
Gross ProfitUS$342.15m
Other ExpensesUS$1.53b
Earnings-US$1.18b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.55
Gross Margin76.54%
Net Profit Margin-264.83%
Debt/Equity Ratio74.4%

How did INSM * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 10:55
End of Day Share Price 2025/12/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insmed Incorporated is covered by 39 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Anita DushyanthBerenberg
Jason ZemanskyBofA Global Research